The membrane-spanning connexin proteins form microscopic intercellular channels that directly connect the cytoplasms of adjacent cells and as such have been implicated in maintenance of tissue homeostasis. They are considered to act as tumor suppressors since their function or expression is frequently aberrant in tumor cells. Several mechanisms appear to be involved in this, but irreversible mutational alterations have not yet been proved to be among them. In this study we have demonstrated for the first time that connexin 43 but not connexin 32 is specifically and quite frequently mutated in human colon sporadic adenocarcinomas. All tumor-associated mutations led to a shift of reading frame and were located in the multifunctional carboxylterminal domain of the protein. Expression of mutated connexin 43 protein was restricted to invasive structures of tumors. These findings suggest that mutational alterations of connexin 43 are involved in advanced stages of progression of human colon cancer towards malignancy.
In the present study, we analysed mutations of the two most common connexins -connexin 32 (Cx32) and connexin 43 (Cx43) -in 29 human sporadic colon neoplasms encompassing a wide range of grades of malignancy from benign adenomatous polyps to poorly differentiated carcinomas.
Employing an immunohistochemical approach, we found that both these connexins are expressed by normal human colon enterocytes. The patterns of subcellular localization of the two connexins in these cells revealed by double immunostaining were to some extent non-overlapping (Figure 1) . Similarly, apart from a very few cases represented by poorly differentiated carcinomas, most of the colon tumors analysed expressed both of these Cx proteins, but to different extents. Since the aim of the study was to assess mutational alterations in the coding area of Cx genes, only tumors that were immunohistochemically positive for these proteins were selected for subsequent genetic analysis.
Indirect heteroduplex mutation screening of the coding region of Cx32 did not reveal any mutationspecific aberrations (not shown).
Similarly, heteroduplex analysis of a part of Cx43 coding for the first half of the protein, including all four membrane-spanning domains, did not reveal any abnormality suggestive of the presence of mutations. However, the patterns of migration of the fragment of Cx43 corresponding to the carboxyl-terminal region of the protein in several tumor samples were aberrant in heteroduplex gels (Figure 2a ). Direct sequencing revealed the presence of several mutations in these cases.
Specifically, in one tumor a silent point mutation in codon 341 (AAC?AAT) was detected ( Figure 2b) . Another tumor had a single nucleotide (T) insertion on the third position after a stop codon (Figure 2c ).
In two other exophitic adenocarcinomas, a single nucleotide deletion in the second position of codon 311 was found (GCT?GTA) (Figure 2d ). The resulting shift of reading frame changed Ala to Val and substituted the next 35 residues followed by a premature stop codon, which shortened the carboxylterminal tail of Cx43 by 36 residues. Sequencing of DNA from blood samples of these two patients confirmed that this mutation was specific to the tumor.
In another adenocarcinoma, insertion of a single nucleotide at the second position of codon 358 was detected (ATT?AAT) (Figure 2e ). Again the resulting shift of reading frame changed Ile to Asn and altered the next 18 residues, followed by an early stop codon, the protein becoming five residues shorter. Overall, three out of six exophytic colon tumors morphologically classified as well or moderately differentiated adenocarcinomas were found to carry frame-shift mutations in the carboxyl-terminal region of Cx43. In addition, in a few other tumor samples with aberrant patterns of migration in heteroduplex gel several single nucleotide mismatches were detected which were due to accidental co-amplification of a Cx43 pseudogene (Fishman et al., 1991) , these have not been taken into consideration as tumor-specific.
The modifications of the amino acid composition of the carboxyl-terminal region due to a mutationally introduced shift of reading frame allowed us to estimate differentially the patterns of expression of mutated and wild type Cx43 in tumor structures. Double immunostaining with a pair of anti-Cx43 antibodies obtained against either the terminal part of carboxyl-terminal region (the domain mutated in tumors) or the internal loop (non-mutated domain) revealed areas of intercellular contacts between normal enterocytes in colon crypts, where Cx protein is usually located, essentially similar (Figure 3a -c) . In contrast, in tumors with mutated Cx43 we observed several structures which had selectively lost immunoreactivity to antibodies against the wild type carboxylterminal domain of Cx43 (Figure 3d ), but retained immunoreactivity to antibodies against the intracytoplasmic loop of Cx43 (Figure 3e ). Strikingly, all such structures were located in the invasive front of tumors ( Figure 3g ). Morphologically these areas were more dysplastic than the rest of the tumor, showing reduced capacity of their cells to form gland-like structures ( Figure 3h ).
Mutational deactivation of a gene during carcinogenesis constitutes strong evidence in favour of its tumor-suppressive capacity. Connexins are a large family of 21 proteins (Willecke, personal communication) with prominent tissue-specific patterns of expression and individual functional properties. The role of connexins in carcinogenesis is well established. The expression and function of some of them in cancerous cells are often aberrant (Neveu et al., 1994; Wilgenbus et al., 1992; Jamieson et al., 1998) . Multiple mechanisms appear to be responsible for this (Yamasaki and Naus, 1996) , but mutations have not previously been shown to be among them. However, it is worth noting that only a few individual connexins, namely Cx32 in hepatocellular carcinomas (Krutovskikh et al., 1994) and Cx37 in lung and endothelial human and rodent tumors (Krutovskikh et al., 1996; Saito et al., 1997 Saito et al., , 2000 were examined on mutations. It appears that the tumor-suppressive capacity of individual connexins is very connexin-species and tissue-specific. Thus, when expression is induced in HeLa cells, only Cx26, but neither Cx43 nor Cx40 suppresses their tumorigenicity (Mesnil et al., 1995) . This implies that mutational deactivation of certain connexins with particularly strong tumor-suppressive potency, but not others, may be etiologically implicated in tumorigenesis in tissues where they are expressed.
Our data show for the first time that mutations of Cx43 may be specifically involved in human colon carcinogenesis. Certain mutational alterations of individual connexins are known to be associated with some human hereditary diseases. Thus mutations of Cx32 are associated with Charcot-Marie-Tooth Xlinked peripheral neuropathy (CMTX) (Bergoffen et al., 1993; Nelis et al., 1999; , mutations of Cx26 (White et al., 1998) and Cx31 (Xia et al., 1998) with deafness, and those of Cx31 (Richard et al., 1998) and Cx30 (Lamartine et al., 2000) with skin disorders. It has also been found that autosomal mutations of Cx43 involving phosphorylatable serine or threonine residues in the carboxyl-terminal tail of the protein are associated with complex human heart malformations (Britz-Cunningham et al., 1995). However, the lack of Figure 1 Expression of Cx32 and Cx43 in normal human colon enterocytes. Double immunostaining for Cx43 (a) and Cx32 (b) revealed some reciprocity in their patterns of subcellular localization in normal colonic enterocytes. While Cx43 was mainly localized in apical parts of the lateral plasma membrane of cells, Cx32 was predominantly situated in its basal parts. Only moderate amount of both connexins was co-localized in mid part of lateral plasma membranes (seen on the overlaid image (c) as yellow). (Bar 10 mm). Cx32 was detected by polyclonal rabbit antibodies raised against a synthetic peptide corresponding to 27 residues located in the cytoplasmic loop of human Cx32 at positions 98-124 (Krutovskikh et al., 1994 . Mouse monoclonal anti-Cx43 antibody (clone CX-1B1) was purchased from Zymed Laboratories Inc., (San Francisco, CA, USA.) For these experiments and for those illustrated in Figure 3 , double immunostaining was performed consecutively. After completion of staining with the first type of primary antibody, a second full round of staining was performed with the other type of primary antibody. Different fluorescent dyes were used to reveal each primary antibody. In order to obtain an enhanced fluorescent signal, the TSA TM fluorescence system (NEN Life Science Products, Boston, MA, USA) was employed according to the manufacturer's protocol. Samples were examined under a Pascal 510 Zeiss laser scanning confocal microscope (Carl Zeiss Jena GmbH, Germany) evidence that these diseases are also associated with increased cancer incidence suggests a major quantitative functional difference between them and cancerassociated Cx mutations.
While most of the Cx mutations associated with non-cancer hereditary or somatic human diseases are single nucleotide mismatches, which alter different domains of the protein, all the mutations we found in colon tumors were located in the carboxyl-terminal tail of Cx43, the multi-functionality of which is already evident, although not yet fully understood. This domain directly interacts with various other proteins (Jin et al., 2000) including cell adhesion ones, such as ZO-1 (Giepmans and Moolenaar, 1998; Toyofuku et al., 1998) and b-catenin (Ai et al., 2000) as well as with its own other domains (Stergiopoulos et al., 1999) . In addition, the carboxyl-terminal tail of Cx43 contains several motifs for phosphorylation by different protein kinases, which is essential for trafficking, gap junction assembly, channel gating and turnover of Cx43 (Lampe and Lau, 2000) . The frame-shift mutations in colon tumors appears to abolish particularly effectively most if not all functional properties of this part of the protein, and thus could have a strong impact on cell growth, morphology and motility that would be critical for cancer progression. We expect further work to show that the products of all these mutant genes disrupt such cell functions. The fact that Cx43 mutations have been found only in invasive structures of exophytic colon adenocarcinomas, but neither among their benign precursors adenomatous polyps, nor in endophytic carcinomas, suggests that Cx43 mutational alterations are limited to this specific type of human colon neoplasms and are involved at a fairly late stage of their progression.
The selective mutational alteration of only Cx43, but not Cx32, in human colon tumors implies that there is considerable Cx-species-and tissue-specificity of the tumor-suppressive capacity of individual connexins. changed Ala to Val and the next 35 residues followed by a premature stop codon (shown on outline as square dotted line, 2 cases); (e) insertion of a single nucleotide (A) at the second position of codon 358 (indicated by an arrow), changed Ile to Asn and the next 18 residues before introduction of an early stop codon (shown on outlines as round dotted line, 1 case). Twenty-nine human sporadic colon tumors were surgically obtained at the St. Petersburg Municipal Coloproctology Center, State Pavlov Medical University, St. Petersburg, Russia. Immediately after surgery, parts of the tumors were frozen and stored in liquid nitrogen. Samples were used either for DNA extraction or cut as 6 mm cryosections for immunostaining and morphological examination. In order to diminish the ratio of DNA and proteins from non-tumor cells inevitably abundantly present with the tumor tissue, tumor glands were selectively dissected under a stereomicroscope from slightly thawed frozen pieces of tumor for further DNA extraction. All DNA samples from tumors were screened for mutations in two individual connexin genes -Cx32 and Cx43 -by the indirect heteroduplex method. For this purpose, partially overlapping fragments of the coding regions of the Cx32 and Cx43 genes, each of approximately 500 base pairs, were amplified by PCR using the following pairs of primers: human Cx32 (CDS P-labeled amplicons were heteroduplexed by denaturing at 958C for 5 min followed by slow stepdown annealing and were resolved by electrophoresis in acrylamide-MDE TM gel (BioWittaker Molecular Applications, Rockland, ME, USA). Dried gels were exposed to Kodak X-omat TM AR films (Kodak Scientific Imaging Film). All samples with an aberrant pattern of migration of heteroduplex bands compared with the control were afterwards subjected to direct sequencing. Samples were amplified by PCR and sequenced with the ABI Prism 1 BigDye terminator cycle system (AB Applied Biosystems, Foster City, CA, USA) in both directions using the same primers as for the heteroduplex analysis. Samples were run on an automated sequencer (Model 310). Sequences were analysed by visual inspection and were considered to be variants only if the trace showed deviation from the wild type on both strands. Several variants detected by direct sequencing were attributed to mismatches between Cx43 and its pseudogene (GI: 181210) Tumor cells forming these structures selectively lost reactivity with antibodies against carboxyl terminal epitope of Cx43 (d), but preserved their affinity to antibody against internal loop of protein (e). Note that stromal fibroblasts surrounding this tumor structure, expressing wild type of Cx43, are positive for both anti-Cx43 antibodies (yellow on the superposed image (f) (Bar 50 mm). (g -h) -Topologic juxtaposition of double immunostaining data shown in d -f with parallel stained H&E cryosections localized a group of tumor structures that were selectively negative to anti-carboxyl terminal Cx43 epitope antibody (enclosed by dotted line on (g) in the invasive front (indicated by white arrows) of adenocarcinoma (Bar 200 mm). As seen on the insert (h), morphology of these tumor structures is more dysplastic, compared to the rest of the tumor represented by gland-like formations (Bar 40 mm). Double immunohistochemical staining was performed with two different anti-Cx43 polyclonal rabbit antibodies. One of the antibodies was obtained against a synthetic peptide, corresponding to 24 residues located in the internal cytoplasmic loop of Cx43 (amino acid positions 119 -142). Specificity of this antibody was confirmed by Western blot (not shown). Another antibody was against a synthetic peptide corresponding to the last 20 residues of the carboxyl-terminal tail of Cx43 (amino acids 363 -382 of the native protein) (kindly provided by Dr E Rivedal, Norway). As we showed before , this antibody has high specificity and affinity to different phosphorylated isoforms of wild type Cx43
